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INVESTIGATION OF THE MECHANISM RESPONSIBLE FOR THE DECREASED 
TRANSCRIPTION OF THE p53 TUMOR SUPPRESSOR GENE IN THE 
HUMAN SQUAMOUS CARCINOMA CELL LINE A253. Ho-Sheng Lin, 
Teresita Munoz-Antonia, and Michael Reiss. Section of 
Medical Oncology, Department of Internal Medicine, Yale 
University, School of Medicine, New Haven, CT. 
The human head-and-neck squamous carcinoma cell line 
A253 was found previously to contain no mutations in the 
coding region of the p53 gene but to express an extremely 
low level of p53 mRNA. This greatly reduced level of p53 
transcription may be the result of a mutation within the 
regulatory region of the gene or the result of an altered 
expression of cellular factors that regulate expression of 
the gene. In order to determine which of these two 
mechanisms is more likely to be responsible, transfection 
experiments were carried out to compare the transcriptional 
activity of a wild-type p53 promoter introduced into the 
A253 cell line to that in a non-neoplastic keratinocyte cell 
line, R12HKc/HPV16. The p53 promoter was linked to a 
luciferase reporter gene. The level of expression of this 
luciferase gene, determined by measuring the light reaction 
catalyzed by its protein product, reflects the 
transcriptional activity of the p53 promoter. Equal levels 

of luciferase activity in both cell lines would indicate 
that the cellular environments of both cell lines were 
similar in their effect on the p53 promoter introduced, and 
therefore, a mutation in the regulatory region of the 
endogenous allele is a more likely mechanism responsible for 
the greatly reduced p53 transcription seen in A253 cells. 
On the other hand, lower luciferase activity in A253 cells 
than in R12HKc/HPV16 cells would indicate that alterations 
in cellular regulatory factor(s) in the A253 cells were 
responsible for this decreased p53 transcriptional activity. 
Unfortunately, the findings from these experiments are 
inconclusive due to difficulties encountered with 
transfecting A253 cells. However, my experiments confirmed 
the existence of two promoter regions in the human p53 gene. 
The activity of the promoter within the 5' 1.2 kbp of intron 
1 was found to be about 75% that of the promoter located 
upstream of the first exon. 
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INTRODUCTION 
A. p53 Timor Suppressor Gene 
The proliferation of normal cells is regulated by the 
protein products of growth-promoting proto-oncogenes 
counterbalanced by the growth-constraining products of tumor 
suppressor genes. Thus, mutations that enhance the 
activities of proto-oncogenes would result in conditions 
that favor the growth of tumor cells. Similarly, genetic 
alterations that inactivate tumor suppressor genes would 
also favor the deregulated growth of cancer cells (1). 
Despite the wide biologic heterogeneity among human cancers, 
a long-standing hope is that the same biochemical pathways 
of growth control would be disrupted in many different kinds 
of cancer. The discovery of such a disrupted pathway would 
provide a central scheme for understanding, preventing, 
diagnosing, and treating these different types of cancer 
(2) . 
The pathway involving the p53 tumor suppressor gene 
appears to fulfill this promise, as alterations of this 
tumor suppressor gene appear to be involved, directly or 
indirectly, in the majority of almost all types of human 
cancers (2, 3). p53 is an important growth regulator and 
exerts its numerous cellular functions through the 
activation or repression of transcription of several 
different genes (3). The wild-type p53 protein forms a 
tetramer which binds to specific DNA sequences, 
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thereby stimulating or inhibiting the transcription of 
downstream genes that control growth (2). Dysfunction of 
the p53 tumor suppressor gene can occur in a variety of 
ways. Analyzing data from 1312 somatic mutations of p53, 
Harris and Hollstein found that 83% were missense mutations, 
6% nonsense mutations, 10% deletions and insertions, while 
1% were silent mutations (3). Furthermore, p53 dysfunction 
can occur via interactions with other cellular proteins, 
such as mdm-2, or viral oncoproteins which either neutralize 
or increase the rate of degradation of p53 proteins (3). 
Missense mutations, which are by far the most common 
mechanism responsible for p53 dysfunction, usually result in 
mutated p53 proteins which fail to bind DNA and which form 
oligomeric complexes with the wild-type p53 form, thereby 
disrupting its normal function (dominant-negative loss-of- 
function mutation). Alternatively, mutant p53 proteins can 
apparently gain new functions, above and beyond inactivating 
the wild-type protein, which promote the growth of cells 
(dominant gain-of-function mutation) (4). Furthermore, the 
effect of these mutant p53 proteins is exacerbated by their 
increased stability allowing them to accumulate to high 
concentration inside the cells. Thus, mutated p53 proteins 
can be doubly detrimental: they not only deprive cells of 
the wild-type p53's antiproliferative effect but can also 
stimulate abnormal cell growth. The wide range of amino 
acid substitutions resulting from various missense mutations 
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appears to result in p53 proteins which range from minimally 
dysfunctional to strongly dominant-negative proteins (1). 
Recent evidence suggests that wt p53 protects cells against 
the inherent mutability of the human genome in somatic cells 
(3). Thus, besides the lack of suppression and/or 
activation of unregulated cell growth, p53 dysfunction would 
render cells hypermutable, resulting in accumulation of 
mutations in cancer cells (3). Mild to moderate DNA damage 
in somatic cells, caused by either gamma-radiation or 
cytotoxic drugs, leads to a rapid increase in wild-type p53 
proteins which serves to arrest cells in G1 phase so that 
repair of DNA damage can take place before proceeding to DNA 
synthesis and mitosis. In contrast, severe DNA damage 
results in p53-mediated cell death by apoptosis. Both 
mechanisms therefore reduce the probability of persistent 
somatic mutations (5, 6, 7). However, cells with mutant or 
absent p53 fail to arrest in G1 and do not undergo apoptosis 
in response to the DNA damage and will therefore tend to 
accumulate mutations and chromosomal rearrangements, 
resulting in rapid evolution of malignant clones and 
metastasis (8, 9, 10, 11). This may also be one of the 
reasons for the increased resistance of cancer cells to 
chemotherapeutic agents and ionizing radiation used in the 
treatment of cancer (12) . 
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B. Previous Work Done in This Laboratory 
Previous studies were performed in this laboratory to 
identify the mechanisms responsible for the inactivation of 
the p53 tumor suppressor genes in eight human squamous 
carcinoma cell lines of different origin (13). The 
mechanisms responsible for the decreased or absent 
expression of the wild-type gene product in these cell lines 
were highly diverse. They included deletion of the gene, 
gene rearrangement, accelerated rate of degradation of the 
p53 protein, and presumed mutations in the regulatory 
sequences of the gene (13). One cell line, A253, 
established from a squamous cell carcinoma of the 
submandibular region of a cancer patient (14, 15) failed to 
express any detectable p53 mRNA transcripts by Northern blot 
analysis (13) nor detectable p53 protein by Western blot 
(13). However, using a very sensitive technique called 
"reverse transcriptase polymerase chain reaction" (RT-PCR), 
a small amount of p53 mRNA was detected (Teresita Munoz- 
Antonia, unpublished data). When the genomic structure was 
evaluated by Southern blot analysis, it was found that A253 
cells contained the expected 7 kb and 2.5 kb Hind III DNA 
fragments and 7.8 kb Bam HI fragment (13). Further study by 
chemical mismatch analysis of PCR-amplified cDNA revealed no 
mutations within exons 2 to 11 in the single p53 carried by 
A253 cells (13). Similarly, sequence analysis of a major 
portion of the first promotor region (210 bases 5' to the 
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first exon) (Figures 1 and 2) failed to reveal any mutation 
(unpublished data). These results indicate that the cell 
line A253 contains a single copy of p53 which does not carry 
any mutations in its coding region nor most of the first 
promoter region but which is transcribed at a subnormal 
level, detectable only by RT-PCR but not by Northern blot. 
Since the dysfunction of p53 in this cell line is apparently 
not due to a mutation nor a deletion in the coding sequence, 
it may be due to a novel mechanism not yet reported in the 
literature. Of interest, Stephen Friend reported recently 
that approximately 10% of human cancers carry a single wild- 
type p53 allele, which is not transcribed (Stephen Friend, 
personal communication). Therefore, I focused my attention 
on uncovering the mechanism responsible for this greatly 
reduced transcription of the p53 allele in A253 cells. One 
possible mechanism may be an alteration in an undefined cis- 
or trans-regulatory element upstream of the p53 promoter 
region or within the introns of the p53 gene such as from a 
point mutation or from a change in methylation pattern. The 
other possibility is an altered expression of cellular 
regulatory factors, such as, for example, an increase in a 
p53 suppressor protein or a decrease in a p53 
transcriptional activator. 
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Figure 1. Map of the human p53 gene. The exons 
1 through 11 are denoted by black boxes. 
emen 1 intron 1 
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Figure 2. Schematic drawing of the 5' end of the 
p53 gene showing the two DNA sites identified by 
Reisman et al. (18) as having promoter activity. Also 
shown is the regions of DNA fragments, containing 
the p53 promoter 1 and 2, that were PCR amplified 
and cloned into the pGL2-Basic Vector in this 
study. 
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C. Regulation of Transcription of the p53 Gene 
The human p53 gene is 20 kbp long and contains 11 
exons. The first exon is noncoding and is followed by first 
intron of 10 kbp (16) (Figure 1). There are some 
discrepancies as to the exact localization of p53 regulatory 
regions. Lamb et al. identified a 350 bp region upstream of 
the 5' end of exon 1 as having full promoter activity (16). 
On the other hand, Tuck et al. analyzed 15 3' and 5' 
promoter deletion constructs and showed that an 85 bp 
fragment located 5' of the first exon retains at least 90% 
of the activity of the 350 bp fragment (17). Finally, 
Reisman et al. proposed the possibility that the p53 gene is 
regulated by two different promoters. They identified a 
first promoter (promoter 1) as being located 100-250 bp 
upstream of the 5' end of the first exon and a second 
promoter (promoter 2) being located within the 5' 1.2 kbp of 
intron 1 (18) (Figures 1 and 2). They also found the 
activity of the second promoter to be 3 to 9 times greater 
in the cell line K562, and 12 to 57 times greater in the 
cell line HL-60, compared to the first p53 promoter (18). 
In addition, when the human cell line HL-60 was induced to 
undergo terminal differentiation, the expression of the 
second promoter increased approximately 5 to 10 times while 
the expression of the first promoter remained constant (19). 
Based on these findings, the investigators concluded that 
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the expression of p53 is differentially controlled in 
normal, differentiating, and transformed cells (18, 19). 
Although most authors (Tuck, Lamb, Reisman, and Bienz- 
Tadmor) agree that there is evidence for the existence of a 
negative regulatory element upstream of the p53 promoter 
region in murine cells, they disagree on the existence of a 
similar negative regulatory region in the human p53 gene 
(16-20). Reisman found evidence for an element upstream of 
the first promoter which negatively regulates the activity 
of the first and second promoter in a human cell line (18). 
However, Lamb and Tuck found no evidence for such an element 
(16, 17). Lamb suggested that either there may not be such 
a negative element or that there may be an additional 
positive regulatory element which counter-balances the 
negative effect of a repressor element (16). Further, some 
investigators have identified a number of potential 
regulatory sites within the human and murine p53 promoter 
region as well as a number of regulatory proteins that may 
bind to these sequences. At least four potential regulatory 
sites have been recognized in murine p53 promoter: These 
include an AP-1 like binding site, a potential SP-1 binding 
site, an NF-1 recognition sequence, and a conserved 
consensus recognition sequence for the basic helix-loop- 
helix (bHLH) family of DNA-binding proteins such as c-Myc, 
USF, and TFE3 (21, 22, 23). Reisman et al. have shown that 
changes in the level of one of these regulatory proteins, 
USF, can alter the level of activity of the murine p53 
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promoter in NIH-3T3, SVT2, and Cos cells. Furthermore, a 
deletion of the bHLH recognition motif leads to a reduction 
in the activitiy of the p53 promoter (21). Although these 
studies were carried out in murine cells, Ronen et al. found 
that a bHLH recognition site is also present in the human 
p53 gene (23) . 
D. Statement of Purpose and Design of Experiments 
The published studies summarized above suggest the 
possible existence of repressor and, perhaps, enhancer 
elements upstream of the human p53 promoter (18, 19). 
Furthermore, a number of potential regulatory sites in the 
p53 gene as well as a number of potential regulatory 
proteins were found in murine cell lines (16-23) . Thus, an 
alteration, either in a regulatory site of p53 or in any of 
the cellular regulatory proteins, might be responsible for 
the marked decrease in p53 gene transcription in A253 cells. 
Either of these would represent novel mechanisms of 
inactivation of p53. In order to investigate these two 
possibilities, I constructed two plasmids, one with the 
wild-type p53 promoter 1 and the other with the wild-type 
p53 promoter 2, linked to a reporter gene called luciferase. 
I then transfected a non-neoplastic keratinocyte cell line, 
R12HKc/HPV16 (which was found previously to contain normal 
amount of normal sized p53 mRNA and wild-type p53 protein) 
(13) and the A253 cell line with either of these plasmids 
and measured the luciferase activity as an indication of the 
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transfected p53 promoter's level of activity. This 
experiment might have one of two possible outcomes. In the 
first scenario, the luciferase activity in A253 cells might 
be equal to that in the non-neoplastic keratinocyte cell 
line. This would mean that the cellular environments in 
both cell lines were similar in their effect on the wild- 
type p53 promoter. We could then conclude that the greatly 
reduced expression of the endogenous p53 allele in the A253 
cell line is most likely due to a mutation in some 
regulatory region(s) of the gene itself. On the other hand, 
if I found that the luciferase activity in A253 cells was 
lower than that in the non-neoplastic keratinocyte cell 
line, this would suggest that the altered cellular 
environment of the A253 cells was somehow responsible for 
the greatly reduced activity of the p53 promoter. 
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MATERIALS AND METHODS 
A. Cell Culture: The squamous carcinoma cell line, A253, 
was obtained from the American Type Culture Collection 
(Rockville, MD) (13). Immortalized non-tumorigenic R12 
HKc/HPVl6 human keratinocytes were established by Dr. L. A. 
Pirisi, University of South Carolina, from a primary culture 
of human neonatal foreskin keratinocytes by transfection 
with recombinant human papillomavirus type 16 DNA, pMHPV16d 
(24). Both cell lines were adapted to and maintained in 
serum-free basal MCDB153-LB medium, supplemented with 70 
ug/ml of bovine pituitary extract (Hammond Cell Technology, 
Alameda, CA), 10 ng/ml of epidermal growth factor, 5 ug/ml 
of insulin, 5 ug/ml of transferrin, 5 ng/ml of selenium, 1.4 
~ 7 . _ Q . . , _ 4 
x 10m M hydrocortisone, 10 M triiodothyronine, 10 M 
ethanolamine, 10M phosphoethanolamine, and 10 ug/ml of 
gentamycin (MCDB 153-LB++) as described by Pirisi et al. 
(24). For the culturing of A253, this complete medium was 
supplemented with 1% fetal bovine serum. The cells were 
grown in T-75 flasks and the media were changed every other 
day. 
B. Construction of Recombinant Plasmids: 
a) Preparation of wild-type p53 promoter 1 and 2 DNA 
fragments: Wild-type p53 promoter 1 and 2 fragments were 
isolated by PCR. For the first p53 promoter, the plasmid 
phuRxCAT (courtesy of Moshe Oren, Department of Chemical 
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Immunology, Weizmann Institute of Science, Israel) 
containing the wild-type p53 promoter linked to a 
chloramphenicol acetyltransferase (CAT) reporter gene was 
used as the DNA template. The 5' primer used was 5' 
GCGCGGTACCTTCCCATCAAGCCCTAGGGC 3' with a Kpnl restriction 
nuclease recognition sequence at the 5'end. The 3' primer 
used was 5' GCGCAGATCTTTTTGAGAAGCTCAAAAC 3' with a Bglll 
restriction nuclease recognition sequence attached to its 5' 
end. A DNA fragment extending from the 5' end of the first 
exon to 842 bp upstream was PCR amplified (26) in buffer 
containing 500 mM Tris, pH 9, 500 mM KC1, and 15 mM MgCl2. 
For the second p53 promoter, genomic DNA from keratinocytes 
was isolated as described by Blin and Stafford (27) and used 
as template. The 5' primer used was 5' 
GCGCGGTACCATTGGGTAAGCTCCTGAC 3' with a Kpnl site at the 5' 
end. The 3’ primer used was 5'GCGCAGATCTTTCAGCCTGCGTCTGGAAC 
3' with a Bglll site at the 5' end (thereby generating a 
Bglll site at the 3' end of the PCR amplified DNA fragment). 
The DNA fragment amplified by PCR extends from the 3' end of 
exon 1 to about 1.2 kbp downstream. It was amplified in 
buffer containing 840 mMTris pH 9, 430 mM KC1, and 13 mM 
MgCl2• The parameters for PCR amplification were one 
initial denaturation at 94°C for 5 minutes followed by 31 
cycles of denaturing at 94°C for 30 seconds, annealing at 
55°C for 1 minute, and elongating at 72°C for 30 seconds for 
the first 30 cycles and 10 minutes for the last cycle. The 
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two DNA fragments (containing the first and second p53 
promoters) amplified are shown in Figure 2. 
b) Ligation of p53 promoter DNA fragment to pGL2-Basic 
Vector: The PCR amplified wild-type p53 promoter 1 and 2 
DNA fragments were phenol-chloroform extracted and 
precipitated in ethanol. They were then digested with the 
restriction nuclease enzymes Kpnl and Bglll to create a 
staggered cleavage at the 51 Kpnl restriction nuclease site 
and the 3' Bglll site. These fragments were then separated 
by electrophoresis in a low melting point agarose gel. 
After the gel slices were melted by heating at 65°C for 5 to 
10 minutes, the DNA fragments were purified by 
phenol:chloroform extraction and ethanol precipitation. The 
pGL2-Basic Vector was obtained from Promega (Fig 3). 
Figure 3. pGL2-Basic Vector. 
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This vector lacks any promoter or enhancer sequences but 
contains a luciferase reporter gene downstream from multiple 
restriction nuclease recognition sites where exogenous 
promoter sequences may be introduced. The pGL2-Basic Vector 
was digested with the restriction endonucleases Kpnl and 
Bglll and ligated with the 842 bp DNA fragment containing 
the first p53 promoter to form the recombinant plasmid pGL2- 
p53prol. Similarly, the vector was ligated to the 1.2 kbp 
DNA fragment containing the second p53 promoter to form 
pGL2-p53pro2. The ligation was carried out by incubating 
100 ng of pGL2-Basic Vector and 45 ng of p53 promoter 
fragment with T4DNA Ligase (Promega, Madison, WI) at 16°C 
for 16 hours in a buffer confining 3 mM Tris-HCl, pH 7.8, 10 
mM MgCl2, 10 mM DTT, and 5 mM ATP. At the end of the 
incubation, the mixtures were heated at 65°C for 10 minutes 
to inactivate the T4DNA Ligase. 
c) Selection of the ligated recombinant plasmids using 
miniprep: The mixtures containing the ligated recombinant 
plasmids were used to transform competent E. coli. cells, 
DH5-alpha. The resulting clones were analyzed by 
restriction enzyme digestion. Based on the size of the 
inserts after Kpnl and Bglll digestion, two clones were 
selected, one containing a 842 bp insert (pGL2-p53prol) and 
the other containing a 1.2 kbp insert (pGL2-p53pro2). Both 
recombinant plasmids were isolated using the Triton-lysozyme 
method and purified by banding on a CsCl gradient. 
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C. Verification of Recombinant Plasmids: 
a) Digestion with various restriction nuclease enzymes to 
verify the recombinant plasmids: The identity of the pGL2- 
p53prol plasmid was verified by digestion with restriction 
nucleases Kpnl, Bglll, Sail, Sadi, Hindlll, and Smal 
individually and in various combinations to determine 
whether they yield DNA fragments of the expected sizes. The 
digestions were carried out by incubating the pGL2-p53prol 
plasmid and the restriction endonuclease(s) at 37°C (except 
for Smal which is incubated at 25°C) for 2 to 3 hours. At 
the completion of digestion, the sizes of the digested 
fragments were analyzed by electrophoresis on a 1% (w/v) 
agarose gel. 
b) Direct DNA sequencing of the p53 promoter 2 fragment 
from pGL2-p53pro2 for further verification: Sequencing was 
performed by annealing an unlabeled primer to the denatured 
p53 promoter 2 DNA fragments for 3 minutes at 95°C, 
extending the primer one base with the 32-P labelled dTTP 
and Sequenase (U. S. Biochemical,Cleveland, OH) for 2 min. 
at 25°C, adding Sequenase termination mixes , and sequencing 
for 5 min. at 37°C (13). 
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D. Other Plasmids: 
a) pRSV-luc plasmid: The plamid pRSV-luc was used in 
experiments that were conducted to determine the optimal 
conditions for transfection. The strong transcriptional 
activity of the long terminal repeat of Rous sarcoma virus 
(29) makes the luciferase activity much easier to measure 
during this optimization process. 
b) pSV-2CAT plasmid: pSV-2CAT plasmid was co-transfected 
with the test plasmid (pGL2-p53prol or pGL2-p53pro2) in 
order to correct for any differences in the luciferase 
activity that was due to the difference in transfection 
efficiency between the two cell lines, A253 and 
R12HKC/HPV16. 
E. Determination of the Level of p53 Transcriptional 
Activity: 
a) Transient transfection assay: 
Three different methods of transfections were tried. 
1) Transient transfections using Lipofectin (GIBCO-BRL, 
Bethesda, MD) were carried out according to the 
manufacturer's specifications. The cells to be transfected 
were grown to 50-90% confluency in 10 cm dishes at 32°C in 
the presence of 5% CO2. 10 ug of recombinant plasmid DNA 
containing the wild-type p53 promoter were mixed with 5 ug 
of pSV-2CAT plasmid and 50 ul of lipofectin solution. The 
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cells were washed twice with the basal MCDB153-LB medium and 
the plasmid and lipofectin mixture was added dropwise to the 
cells on the plates. The plates were then incubated at 32°C 
for 5-6 hours before one ml of complete medium (MCDB153- 
LB++) was added. The plates were then incubated overnight 
at 32°C. Twenty-four hours after transfection, the 
transfection medium was completely replaced with 10 ml 
MCDB153-LB++ complete medium. The cells were incubated for 
an additional 24 hours before proteins were extracted. 
2) Transient transfections using electroporation were 
carried out essentially according to the protocol described 
by Reiss et al. (28). Cells grown to about 80% confluency 
were detached by trypsinization and resuspended in 0.5 ml of 
ice-cold phosphate buffered saline. 50 ug of pRSV-luc and 
50 ug of pSV-2CAT plasmids were added to the cell suspension 
and incubated for 10 minutes in ice. The mixture was then 
transferred to sterile 0.4 cm polysterene cuvettes provided 
with two aluminium electrodes as described by Potter et al. 
(30). An electric pulse of 100 to 200 V was then applied to 
the electroporation chamber. After the shock, the cell 
suspension was kept in ice for 10 minutes, diluted with warm 
culture medium, and transferred to a new dish. The cells 
were incubate at 37°C for 30 hours before they were 
harvested for protein extraction. 
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3) Transient transfections by calcium phosphate 
precipitation were also carried out. 12-16 hours prior to 
transfection, 1.5 x 10^ cells were plated onto 10 cm dishes. 
The medium was replaced with fresh MCDB153-LB++ two hours 
before transfection. 22.5 ug of pRSV-luc and 11.25 ug of 
pSV-2CAT were mixed with 962 ul of TE (ImM Tris and 0.ImM 
EDTA, pH 7.9) and 141 ul of 2M CaCl2 to a final volume of 
1125 ul. This mixture was added slowly to the 2xHBS 
solution (280mM NaCl, 50mM hepes, 1.5mM Na2HP04, pH 7.1) 
while simultaneously bubbling the 2xHBS with a 1 ml pipette 
attached to a mechanical pipettor. After incubation for 40 
minutes at room temperature, the mixture was added dropwise 
to each plate. The cells were then incubated at 37°C for 4 
hours before they underwent glycerol shock using 11.25 ml of 
15% glycerol for 1-2 minutes to increase transfection 
efficiency. After washing the glycerol off with MCDB153- 
LB++, the cells were incubated for 48 hours at 37°C 
incubator before protein extraction. 
b) Preparation of protein extract: Thirty hours (for 
electroporation) and forty-eight hours (for lipofectin and 
calcium phosphate precipitation) after the start of 
transfection, the plates were rinsed with ice-cold PBS and 
the cells were gently scrapped with a rubber policeman using 
1.5 ml of scrapping buffer (0.04 M Tris, pH 7.4, 0.15 M 
NaCl, and 0.001 M EDTA). The cells were then transferred to 
a microcentrifuge tube and centrifuged at 14,000 rpm for 4 
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minutes at 4°C. The supernatant was discarded and the cell 
pellet was resuspended in 50 ul of extraction buffer (100 mM 
KH2PO4 and 1 mM DTT). The cells were lysed by 3 cycles of 
freezing in a dry ice/ethanol bath for two minutes and 
thawing in a 37°C water bath for 2 minutes. The cell debris 
was then collected by spinning it down in a microcentrifuge 
The supernatant containing the protein extract was 
transferred to a clean tube and stored at -70°C. 
c) Determination of protein concentration: The 
concentration of protein extract was determined using the 
Bio-Rad Protein Assay (BIO-RAD Laboratories, Richmond, VA) 
based on the method of Bradford (31). 
d) Luciferase assay: The reporter gene luciferase codes 
for an enzyme which oxidizes luciferin to produce a photon. 
The measurement of the light intensity can then give an 
accurate indication of the level of expression of the gene 
and, indirectly, of the transcriptional activity of the 
promoter which drives the reporter gene. This measurement 
is done using the Luciferase Assay System (Promega, Madison, 
WI) according to the manufacturer's specifications. A 
measured amount of protein extract was diluted to a volume 
of 20 or 40 ul and mixed with 100 or 200 ul of luciferase 
assay reagent, respectively. These mixtures were 
immediately placed in a Series 20 Barthda Luminometer 
(Turner Designs, Sunnyvale, CA) for measurement of light 
production. 
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e) Quantitative determination of chloramphenicol acetyl 
transferase (CAT) in transfected cells: The amount of CAT 
enzyme was determined using the CAT ELISA Assay from 
Boehringer Mannheim Corporation (Indianapolis, IN) according 
to the manufacturer's protocol. Briefly, 50 ug of protein 
extract was diluted to a volume of 200 ul using sample 
buffer (Solution III from the CAT ELISA Assay kit). 
Different dilutions of CAT protein were used to create a 
standard curve. The protein extract to be measured and the 
standards were incubated in a 96 well plate containing anti- 
CAT antibodies for 2 hours at 37°C while rocking slowly. 
The solution was then discarded, the wells washed four times 
with washing buffer containing 0.5% (v/v) Tween-20 in PBS 
buffer, and a digoxigenin-labeled antibody to CAT was added. 
After one hour incubation, the solution was discarded and 
wells washed as before. An antibody to digoxigenin 
conjugated to peroxidase was then added for another one hour 
incubation. Lastly, the peroxidase substrate was added. 
Since the peroxidase enzyme cleaves the substrate to produce 
a colored precipitate, the absorbance of the sample 
precipitate can be determined and is an indication of the 
level of CAT protein present in the cell extracts. 
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RESULTS 
Verification of Recombinant Plasmids: 
After ligation of the p53 promoter 1 and p53 promoter 2 DNA 
fragments into the pGL2-Basic Vector and transformation into 
competent E. coli. cells, the recombinant plasmids were 
isolated and digested with the restriction nucleases Kpnl 
and Bglll. Figure 4 shows that 4 out of 6 clones yielded 
the expected 5.6 kbp fragment for the linear pGL2-Basic 
Vector and the 0.84 kbp fragment for p53 promoter 1 and 9 
out of 13 clones had the expected 5.6 kbp pGL2-Basic Vector 
fragment and the 1.2 kbp fragment for the p53 promoter 2. 
Clone 1A was grown for isolation of the plasmid pGL2-p53prol 
by Triton-lysozyme method and clone 20 was selected for the 
plamid pGL2-p53pro2. The recombinant plasmid pGL2-p53prol 
was digested using Sall+SacII, Knpl+Bglll, and SacII alone. 
The sites for these restriction nucleases are shown on 
Figure 5, and Figure 6 shows that the digestions yielded 
fragments of the correct size on gel electrophoresis. 





'' 'V zp%l ‘ /' 
^-^4’ 
Figure 4. Digestion of plasmid DNA prepared from 
transformed E. coli. (DH5-alpha) colonies. The 
restriction nucleases used were Kpnl and Bglll which 
released the inserted p53 promoter fragment from the 
recombinant plasmid. Lane one shows the sizes of 
DNA standard lambda DNA EcoRl/Hindlll prepared by V. 
F. Vellucci. Lanes 1A to IF show the digestion of 
plasmid DNA from colonies that were transformed by 
the ligated product of pGL2-basic vector and p53 
promoter 1 fragment. Lanes 1A; 1C, ID, and IF all 
showed the expected fragment sizes of 0.84 kbp for 
p53 promoter 1 fragment and 5.6 kbp for the pGL2- 
basic vector. Lanes 2J to 2V represent the 
digestion of plasmid DNA from colonies that were 
transformed by the ligated product of pGL2-basic 
vector and p53 promoter 2 fragment. Lanes 2J, 2K, 
20, 2P, 2Q, 2R, 2S, 2T, and 2U all showed the 
expected fragment sizes of 1.2 kbp for the p53 
promoter 2 fragment and 5.6 kbp for the pGL2-basic 
vector. 
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expected sizes of 
Sail and SacII --> 






from digestion bv: 
and 3.45 kbp 
and 5.60 kbp 
4 kbp 
Figure 5. pGL2-p53prol recombinant plasmid 
restriction nuclease sites and expected sizes 
of fragments from nuclease digestions. 
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Figure 6. Digestion of the recombinant plasmid 
pGL2-p53prol by Sail and SacII (lane 2), Kpnl 
and Bglll (lane 3), and SacII alone (lane 4). 
Lane 1 shows the sizes of the standard lambda 
DNA EcoRI/Hindlll stardard. Lane 2 shows the 
2.95 kbp and 3.45 kbp digest products from Sail 
and SacII; lane 3 shows the 5.6 kbp and .84 kbp 
products from Kpnl and Rglll digestion; lane 4 
shows the linear 6.4 kbp fragment from single 
cut made by SacII; and lane 5 shows the undigested 
pGL2-p53prol cirular plasmid of 6.4 kbp. The 
result of these digestions confirmed that the 
correct recombinant plasmid was cloned since they 
produced fragments of expected sizes. 
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The restriction nuclease digestion sites for pGL2-p53pro2 
together with the expected sizes of digestion fragments are 
shown in Figure 7. The result of the digestion is shown in 
Figure 8. Surprisingly, lanes 8 and 9 revealed fragments of 
unexpected sizes. On lane 8, the digestion by Sail and Smal 
should give fragments of 2.97 kbp, 2.85 kbp, and 0.96 kbp; 
instead, fragments of about 3.9 kbp and 2.85 kbp are seen. 
On lane 9, digestion by Smal alone should give rise to 
fragments of 5.8 kbp and 0.96 kbp; instead, a fragment of 
similar size to lane 10 is seen suggesting only a single cut 
was made by Smal. The observed sizes of digestion products 
in lanes 8 and 9 would be expected if there was no Smal 
restriction site within the 1.2 kbp p53pro2 fragment, 
leaving only one Smal site on the pGL2-vector close to the 
Kpnl site. Thus, although there is a Hindlll site at the 
expected region within the p53pro2 fragment as shown in lane 
6, the results from lane 8 and 9 appear to indicate that the 
expected Smal site within the p53pro2 fragment is missing. 
This raises the possibility that there is a Smal 
polymorphism within the p53pro2 fragment or that the 
fragment cloned is not really the p53pro2 fragment. In 
order to resolve this issue, direct DNA sequencing of the 5' 
and 3' region of the 1.2 kbp fragment was done. 150 base 
pairs were read from the 5' end and also from the 3' end 
which matched the wild-type sequence of p53 promoter 2 
region. This verifies that the right fragment had been 
cloned into the pGL2-Basic Vector. Unfortunately, the 
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putative Smal site is 260 base pairs from the 3' end and I 
was therefore unable to confirm the existence of a 
polymorphism at this site. Since the p53pro2 fragment is 
derived from the intron 1 region, which may not be an 
important region to be conserved during evolution, it is 
possible that a Smal polymorphism exists among individuals. 
Polymorphisms within intron 1 of p53 have also been reported 
by others (32 , 33 ) . 





expected sizes of fragments from restriction 
nuclease digestion: 
HindiII 
Kpnl and 3glII 
Sail and Smal 
Smal 
Sail 
5.7 kbp and 1.08 kbp (lane 6) 
--> 5.55 kbp and 1.2 kbp (lane 7) 
- - > 2.97 kbp, 2.85 kbp, and 
0.96 kbp (lane 8) 
--> 5.8 kbp and 0.96 kbp (lane 9) 
--> linear 6.75 kbp (lane 10) 
if Smal site is absent in the p53 promoter 2 
fragment: 
Sail and Smal --> 3.9 kbp and 2.85 kbp (lane 8) 
Smal --> linear 6.75 kbp (lane 9) 
Figure 7. pGL2-p53pro2 recombinant plasmid 
restriction nuclease sites and the expected sizes 
of DNA fragments from nuclease digestions. If 
the Smal restriction site is missing in the p53 
promoter 2 fragment, then fragment sizes different 
from that expected would appear on lanes 8 and 9. 
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Figure 8. Restriction nuclease digestion of 
the recombinant plasmid pGL2-p53pro2. Lane 1 
shows the sizes of the standard lambda DNA 
EcoRI/Hindlll and lanes 2 through 5 are the 
digestion products of pGL2-p53prol as shown 
earlier on Figure 6. Lanes 6 to 11 show the 
digestion products of pGL2-p53pro2. In lane 6 
the expected 5.7 kbp and a 1.08 kbp fragments 
from a Hindlll digestion are seen. Lane 7 also 
reveals the expected sizes of fragments, 5.55 
kbp and 1.2 kbp, from digestion by Kpnl and Bglll. 
A linear fragment of 6.75 kbp from the single cut 
of Sail is shown on lane 10, and lane 11 shows the 
circular 6.75 kbp fragment from an undigested 
pGL2-p53pro2 plasmid. Lanes 8 and 9 revealed 
fragments of unexpected sizes. On lane 8, the 
digestion by Sail and Smal should give fragments 
of 2.97 kbp, 2.85 kbp, and 0.96 kbp; instead, 
fragments of 3.9 kbp and 2.85 kbp are seen. On 
lane 9, digestion by Smal alone should give rise 
to fragments of 5.8 kbp and 0.96 kbp; instead, a 
fragment of 6.75 kbp is seen. 
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Transient Transfection Studies: 
The difference in the measured activity of a reporter 
protein (CAT or luciferase) by a particular promoter, in the 
two different cell lines, A253 and R12HKc/HPV16, may be due 
to many factors: 
1. Different number of cells present in different cell 
culture plates. This is corrected by expressing the level 
of reporter protein activity per unit of protein extract. 
2. Difference in the transfection efficiency between the 
two cell lines. In order to correct for this factor, the 
control plamid pSV-2CAT was transfected at the same time 
with the test plamid (pRSV-luc, pGL2-p53prol, or pGL2- 
p53pro2). Assuming that the control plamid and test plasmid 
are transfected with equal efficiency into the same cell 
line and assuming that the two cell lines affect the SV-2 
promoter similarly, then the expression of the luciferase 
activity per ug of protein over CAT enzyme concentration 
would correct for any difference due to different 
transfection efficiency between the two cell lines. 
3. Differences in the cellular environment (e.g. presence 
or absence of certain gene regulatory proteins) of the two 
cell lines which alter the activity of a particular promoter 
causing a difference in the expression of reporter protein. 
This is the difference which we expect to measure in these 
experiments. 
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Optimization of Transfection Conditions For A253 and 
R12HKc/HPV16 Cell Lines Using the Plasmids pRSV-luc: 
Three different methods of transfections (electroporation, 
calcium phosphate precipitation, and lipofection) were 
tested in order to determine which technique would yield the 
highest transfection efficiency in the two cell lines. The 
plasmid pRSV-luc was used in these optimizing experiments 
because of the very strong transcriptional activity of the 
long terminal repeat of Rous sarcoma virus which makes the 
luciferase activity much easier to measure (29). 
1. Transfection of A253 and R12HKc/HPV16 Cells Using 
Electroporation Technique: 
Each cell line was shocked using Gene Pulser apparatus & 
capacitance extender (Bio-Rad Laboratories, Hercules, CA) 
with an electric pulse of 100 V or 200 V in the presence of 
50 ug of the test plasmid, pRSV-luc. Control cells were 
shocked at 200 V without the pRSV-luc plasmid. Table 1 
shows that the transfection efficiency under this 
experimental condition was low for both cell lines. The 
measured luciferase activity per ug protein from cells 
shocked in the presence of pRSV-luc is close to the 
background value obtained with mock-transfected cells. 
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luciferase activity/ug protein 
A253 Cells: 100 V with pRSV-luc 2.27/ug protein 
200 V with pRSV-luc 2.90/ug protein 
200 V (control) 0.72/ug protein 
R12HKc/HPV16: 100 V with pRSV-luc 0.81/ug protein 
200 V with pRSV-luc 2.16/ug protein 
200 V (control) 1.14/ug protein 
Table 1. Measured luciferase activity per ug protein from 
A253 and R12HKc/HPV16 cells transfected with pRSV-luc using 
electroporation at 100 V and 200 V. 
2. Transfection of A253 and R12HKc/HPV16 Cells Using 
Calcium Phosphate-DNA Precipitate: 
Calcium phosphate transfection using pRSV-luc and pSV-2CAT 
was also tried. The luciferase activity measured was also 
low. For the A253 cells, the luciferase activity is shown 
in Table 2. The R12HKc/HPV16 cells appeared to be killed 
under the conditions used in these experiments. 
luciferase activity/ug protein 
A253 Cells: with glycerol shock 1.50/ug protein 
without glycerol shock 2.10/ug protein 
Table 2. Luciferase activity of the A253 cells transfected 
with pRSV-luc using the calcium phosphate precipitate method 
with or without glycerol shock. 
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3. Transfection of A253 and R12HKc/HPV16 Cells Using 
Lipofectin: 
Experiments varying the incubation time and the confluency 
of the cells were carried out to determine the optimal 
conditions for transfection by lipofection. Table 3 shows 
the results from the experiment in which the length of 
incubation time (from the start of transfection to the 
extraction of proteins from the cells) was varied. Both the 
A253 and R12HKc/HPV16 cell lines yielded the greatest 
luciferase activity at 48 hour post-transfection. 
time luciferase activity/ucr protein 












Table 3. Luciferase activities from A253 and R12HKc/HPV16 
cell harvested at different time after transfection with 
pRSV-luc. 
Another variable tested was the confluency of the cells in 
the plate at the time of transfection. Cells were grown to 
between 50-90% confluency at the time of transfection with 
pRSV-luc to determine the optimal cell density. The 
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incubation time was kept at 48 hours. The results are shown 
in Table 4 and appear to indicate that for both A253 and 
R12HKc/HPV16 cells, 80-90% confluency at the time of 
transfection yielded the highest rate of transfection 
efficiency and therefore the highest luciferase activity. 
confluency luciferase activity/ucr protein 












Table 4. Luciferase activity of A253 and R12HKc/HPV16 cells 
from transfection with pRSV-luc at different confluency 
levels. 
From these experiments, transfection using lipofectin appear 
to yield the highest transfection efficiency in both the 
A253 and the R12HKc/HPV16 cells. The optimal incubation 
time was determined to be 48 hours and the optimal cell 
density at the time of transfection was at 80-90% 
confluency. However, it is also clear from these 
experiments that the measured luciferase activity per ug 
protein in the A253 cells was much lower than that in the 
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R12HKc/HPV16 cells. Since both of these cell lines were 
transfected with the test plasmid, pRSV-luc, the lower 
luciferase activity in A253 ceils appears to be due to an 
intrinsically low transfection efficiency of these cells. 
Determination of the Level of p53 Promoter Activities in the 
Cell Line A253 and a Non-neoplastic Keratinocyte Cell Line, 
R12HKc/HPV16: 
After the transfection condition using lipofectin was 
optimized in the previous experiments, the A253 and 
R12HKc/HPV16 cells were transfected using the recombinant 
plasmids, pGL2-p53prol and pGL2-p53pro2, in order to 
determine the level of p53 promoter 1 and promoter 2 
activity in these two cell lines. The incubation time was 
kept at 48 hours. Table 5 shows the luciferase activity per 
ug protein, amount of CAT enzyme per ug protein, and the 
luciferase activity over CAT protein concentration to 
correct for difference due to transfection efficiency. Even 
though the values for the luciferase activity per CAT 
protein appear to suggest that the transcriptional activity 
of the p53 promoter 1 and 2 was much lower in the A253 cells 
compared to that in the R12HKc/HPV16 cells, however, the 
luciferase activities from the A253 cells were so low that 
interpretation of these data may be unreliable. 
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luc/ucf protein CAT/ua orotein luc/CAT 
A2 53 Cells: 
p53 promoter 1 1.7/ug protein 0.47/ug protein 3.56 
p53 promoter 2 2.2/ug protein 0.82/ug protein 2.73 
R12HKC/HPV16 Cells: 
p53 promoter 1 392.7/ug protein 6.9l/ug protein 56.82 
p53 promoter 2 357.6/ug protein 6.58/ug protein 54.30 
Table 5. Results of the transfection experiment in A253 and 
R12HKc/HPV16 cells using the recombinant plasmids, pGL2- 
p53prol and pGL2-p53pro2. 
Comparison of the Level of Transcriptional Activities of p53 
Promoter 1 and Promoter 2 in the R12HKc/HPV16 Cells: 
The transcriptional activity of promoter 2 had previously 
been found to be 3 to 9 times greater in the human leukemic 
cell line K562 and 12 to 57 times greater in the human 
leukemic cell line HL-60, compare to that of the promoter 1 
(18). Our previous experiments have shown that transfection 
of plasmids into the R12HKc/HPV16 cells was largely 
successful with good measured luciferase activity. Thus, we 
decided to use R12HKc/HPV16 cell line to compare the 
strength of transcriptional activity between the p53 
promoter 1 and promoter 2. As shown in Table 6 under the 
luc/CAT section, the transcriptional activity of the first 
promoter construct was found to be twice that of the second 
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promoter in one case and about the same as the second 
promoter in another experiment. 
luc/ucr protein CAT/ucr protein luc/CAT 
exp. 1: 
p53 promoter 1 2141.9/ug protein 2.32/ug protein 922.0 
p53 promoter 2 978.5/ug protein 2.06/ug protein 473.01 
exp. 2 : 
p53 promoter 1 392.7/ug protein 6.91/ug protein 56.82 
p53 promoter 2 357.6/ug protein 6.59/ug protein 54.30 
Table 6. Luciferase activities of p53 promoter 1 and 
promoter 2 in the cell line, R12HKc/HPV16, expressed per ug 
protein and per unit CAT protein concentration. 

LIN p53 DYSFUNCTION IN A253 CELLS 37 
DISCUSSION 
p53 tumor suppressor gene is the most commonly- 
identified mutated gene in human tumors to date. About 70% 
of the 6.5 million people diagnosed with cancer each year 
carry p53 mutations in their tumors (34). In addition, 
approximately 30% of the remaining cases carry a single 
wild-type p53 allele, which is not transcribed (Stephen 
Friend, personal communication). This pervasive involvement 
of p53 dysfunction in almost all types of human cancers 
raises the hope that understanding the mechanism of p53 
inactivation will provide new leads for the prevention, 
diagnosis, and treatment of cancer. The finding that a 
transfected wild type p53 gene is able to suppress growth 
and/or tumorigenicity of a variety of human cancer cell 
lines (35-44) has raised numerous new therapeutic 
opportunities. One such therapy would involve the 
introduction of a wild-type copy of the p53 gene into human 
tumors via gene therapy. Such therapy would have a high 
therapeutic index since the overexpression of wild-type p53 
transfected into nonmalignant cells has minimal deleterious 
effects (3). In fact, one such trial has already been 
approved for 14 patients with advanced lung cancer (34). 
Perhaps, one of the most widely investigated area 
involves the evaluation on the use of p53 status as a 
potential biologic marker to aid in treatment decisions, in 
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assessing prognosis, and in detecting early tumors (45-59). 
By far, the most common mechanism responsible for p53 
dysfunction is a missense mutation, accounting for about 83% 
of cases (3). Such mutations usually result in a mutated 
p53 protein with increased stability, increasing their half- 
life from minutes to hours and allowing them to accumulate 
to high concentration inside the malignant cells (60, 61). 
This increased level of p53 protein in these malignant cells 
can be detected immunohistochemically using antibodies 
against the p53 protein (3). On the other hand, the 
relatively low levels of wild-type p53 protein in normal 
cells will not be detected using this immunohistochemical 
analysis (3). This finding is potentially very useful 
clinically because immunocytochemistry is a simple technique 
which can be used to detect p53 mutations in tissue biopsy 
materials, sputum cytologic specimens, or cells from 
aspirates (3). This could lead to early detection of cancer 
as well as aid in assessing the prognosis and determining 
the response to treatment. Although promising, the use of 
immunohistochemical techniques to detect p53 dysfunction is 
not perfect. As stated before, the majority (83%) of cases 
of p53 dysfunction are due to missense mutations that lead 
to mutant p53 proteins. These mutant proteins usually, but 
not always, accumulate to high levels in the cells. Harris 
and Hollstein reported that of the 100 tumors with p53 
missense mutations they examined, greater than 90% were 
shown to have abnormal accumulation of p53 proteins, not 

LIN p53 DYSFUNCTION IN A253 CELLS 39 
100% (3). Furthermore, when the other mechanisms 
responsible for 17% of the p53 dysfunction result in 
truncated protein or a normal, decreased, or even absent 
level of p53 protein, the immunohistochemical technique will 
fail to detect them. Cells carrying these types of 
inactivation would show up as false negatives. The 
sensitivity for detecting cells carrying p53 defects can be 
increased by methods such as restriction fragment length 
polymorphism analysis to detect deletion or single-stranded 
conformation polymorphism analysis to detect p53 gene 
mutation. However, neoplastic cells such as the A253 cell 
line being investigated in this study in which the p53 gene 
contains no mutation and the p53 protein is present at a 
very low level will not be detected by any of these 
techniques. The elucidation of other mechanisms which may 
be responsible for p53 dysfunction is therefore important 
clinically. If, for example, a cellular factor is 
identified as responsible for the suppression of p53 gene 
expression, this factor may represent a new oncogene and may 
serve as a biologic marker for detection of these neoplastic 
cells. 
In this study, we have successfully constructed two 
recombinant plasmids, one containing the first promoter 
region and the other containing the second promoter region 
of p53 driving the reporter gene, luciferase. Our 
transfection experiments indicate that there is indeed 
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promoter activity in the 5' 1.2 kbp of the intron region 
which is in agreement with the observation made by Reisman 
et al. In their study, they found the activity of the 
second p53 promoter to be 3 to 9 times greater than the 
first promoter in the cell line K562 and 12 to 57 times 
greater in the cell line HL-60 (18). However, in our 
transfection experiments using R12HKc/HPV16 cells, we found 
the transcriptional activity of the second promoter to be 
half that of promoter 1 in one case and equal to that of 
promoter 1 in another instance (Figure 7). This discrepancy 
between our studies and that of Reisman's group may be due 
to at least two factors. First, the second p53 promoter 
region we used in our experiments was cloned from a non- 
tumorigenic cell line immortalized by transfection with 
recombinant human papillomavirus type 16 DNA, and therefore, 
it can be assumed to be wild-type. On the other hand, 
Reisman et al. isolated their second promoter region from a 
transformed human cell line SV80 which overexpresses p53 
proteins. In their paper, they raised the possibility that 
there may be mutations which activate the second promoter 
region in the cell line SV80 which may therefore be 
responsible for the overexpression of p53 proteins (18). 
This possibility could account for the difference between 
their data and our own observation. Secondly, we performed 
the transfections of the recombinant plasmids containing the 
wild-type p53 promoters into a non-neoplastic keratinocyte 
cell line, R12HKc/HPV16. Reisman's group, however, 

LIN p53 DYSFUNCTION IN A253 CELLS 41 
conducted their experiments using the human leukemic cell 
lines HL-60 and K562, both derived from leukemic patients 
(18). In their study, they found that the level of 
transcriptional activity of the first p53 promoter was about 
the same in both of these cell lines. The activity of the 
second promoter, however, differs greatly between the HL-60 
and K562 cell lines. This difference in the second 
promoter's activity account for their observation that the 
activity of the second p53 promoter is greater than the 
first promoter by a factor of about 3 to 9 times in the cell 
line K562 and by a factor of 12 to 57 times in the cell line 
HL-60. This difference of transcriptional activity of p53 
promoter 2 may be due to differences in the cellular 
factor(s) present in these two cell lines. The high level 
of p53 promoter 2 activity in these two cell lines may 
possibly be due to certain abnormally expressed activator 
proteins that act on the second promoter, and that the HL-60 
cell line has a higher level of such putative activators 
than the K562 cell line. It may also be possible that the 
R12HKc/HPV16 cell line we used in our experiment lacks this 
abnormal activator protein and therefore expresses a lower 
level of p53 promoter 2 activity. The possibility of an 
activator protein can also explain the finding by Reisman et 
al. that during the terminal differentiation of the HL-60 
cells, the expression from p53 promoter 2 was increased 5- 
to 10-fold, while expression from the first promoter 
remained constant (19). Clearly, it is possible that when 
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this transformed cell line was induced to undergo 
differentiation, it may increase the level of certain 
cellular factor responsible for the activation of the second 
p53 promoter. 
Multiple transfection experiments were conducted in 
order to compare the level of transcriptional activity of 
the wild-type p53 promoters in the squamous carcinoma cell 
line A253 and a non-neoplastic keratinocyte cell line 
R12HKc/HPV16. The two possible results which we would 
expect from these experiments are that either the level of 
transcriptional activities of the p53 promoter in the two 
cell lines are the same or that the level of activity in the 
A253 cells are much lower than that in the R12HKc/HPV16 
cells. The result would allow us to determine if the 
mechanism responsible for the greatly reduced level of p53 
expression in the squamous carcinoma cell line A253 is more 
likely due to alteration in the regulatory region of the 
gene (if the activities are the same in the two cells) or 
due to alteration in the gene regulatory proteins (if the 
activities of the A253 is much lower than that in the 
R12HKc/HPV16). However, these transfection experiments were 
unsuccessful mainly due to the difficulty encountered in 
transfecting the A253 cells. Although we were able to 
obtain a satisfactory level of luciferase activity from the 
transfection experiments done in R12HKc/HPVl6 cells, the 
luciferase activity measured in the transfected A253 cells 
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was consistently very poor, close to the baseline and 
therefore uninterpretable. Numerous attempts were made to 
optimize the transfection conditions but the improvement in 
transfection efficiency seen in A253 cells was not 
significant. Further investigations in the search for a 
possible novel mechanism of p53 inactivation will require 
the finding of an effective way of introducing the DNA 
plasmids into the A253 cell line. A second possibility is 
to conduct these experiments on another cell line, if one 
such exists, that has the same attributes as the A253 cells, 
such as the existence of an intact, nonmutated p53 gene but 
a very low level of p53 mRNA production. 
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